Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Aeglea BioTherapeutics, Inc. (AGLE) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
08/11/2023 8-K Quarterly results
Docs: "Aeglea BioTherapeutics, Inc. Condensed Consolidated Balance Sheets June 30, December 31, 2023 2022 ASSETS CURRENT ASSETS Cash and cash equivalents $ 235,358 $ 34,863 Marketable securities — 20,848 Development receivables 1,646 375 Prepaid expenses and other current assets 2,882 6,172 Total current assets 239,886 62,258 Restricted cash 1,317 1,553 Property and equipment, net — 3,220 Operating lease right-of-use assets 2,316 3,430 Other non-current assets 10 683 TOTAL ASSETS $ 243,529 $ 71,144 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable $ 2,854 $ 677 Forward contract liability 164,382 — CVR liability 10,500 — Operating lease liabilities 4,331 625 Deferred revenue 930 517 Accrued and other current liabilities 28,427 12,837 Related party accounts payable 20,810 — ..."
08/11/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
07/27/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma"
07/14/2023 8-K Quarterly results
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/19/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/11/2023 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results $39.8 million of cash and cash equivalents, marketable securities, and restricted cash as of March 31, 2023"
04/25/2023 8-K Quarterly results
03/13/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/02/2023 8-K Investor presentation, Quarterly results
Docs: "Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates Jeffrey Goldberg, experienced biotech executive, appointed president and CEO; further strengthened senior management team with appointments of chief medical officer and chief product officer $57.3 million of cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2022, which is expected to fund operations into the fourth quarter of 2023",
"7.0 14.0 21.5 36.0 ER FR PR NR"
01/18/2023 8-K Quarterly results
01/09/2023 8-K Investor presentation
Docs: "Corporate Presentation",
"Corporate Presentation"
01/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
12/19/2022 8-K Quarterly results
11/30/2022 8-K Quarterly results
11/15/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
10/04/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/06/2022 8-K Investor presentation
Docs: "Corporate Presentation",
"Corporate Presentation"
08/25/2022 8-K Resignation/termination of a director
08/18/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
07/19/2022 8-K Quarterly results
07/07/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
05/06/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/12/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD",
"Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency BLA submission provides FDA with all pegzilarginase program data to review in detail; Aeglea looks forward to working collaboratively with the FDA on next steps in the review process",
"Corporate Presentation"
03/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/08/2022 8-K Quarterly results
02/10/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy